Source: Pharamceutical Technology

Phanes: Phanes acquires second FDA orphan designation for bispecific antibody

PT217 has received orphan drug designations from the FDA for the treatment of neuroendocrine carcinoma in addition to small cell lung cancer.

Read full article »

Phanes's Competitors | Phanes's News | Phanes's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

Founder & CEO

Ming Wang

CEO Approval Rating

90/100

Phanes is a California-based biotechnology company that provides drug discovery, development and related services for the treatment of cancer and opthalmic diseases.